Outcomes of an international multicenter registry on EUS-guided gallbladder drainage in patients at high risk for cholecystectomy*

Authors
A.Y. Teoh¹, Manuel Perez-Miranda², Rastislav Kunda³, Sang Soo Lee⁴, Shayan Irani⁵, Paul Yeaton⁶, Siyu Sun⁷, Todd Huntley Baron⁸, Jong Ho Moon⁹, Bronte Holt¹⁰, Christopher J.L. Khor¹¹, Rungsun Rerknimitr¹², Amol Bapaye¹³, Shannon Melissa Chan¹, Hyun Jong Choi¹⁹, Theodore William James⁸, Pradermchai Kongkam¹², Yun Nah Lee⁹, Parth Parekh¹⁴, Wiriyaporn Ridtitid¹², Carlos Serna-Higuera², Damien M.Y. Tan¹¹, Raul Torres-Yuste²

Institutions
¹ Department of Surgery, Prince of Wales Hospital, The Chinese University of Hong Kong, Shatin, Hong Kong
² Department of Medicine, University Hospital Rio Hortega, Valladolid, Spain
³ Department of Surgical Gastroenterology, Aarhus University Hospital, Aarhus, Denmark
⁴ Division of Gastroenterology, Department of Internal Medicine, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea
⁵ Digestive Disease Institute, Virginia Mason Medical Center, Seattle, Washington, United States
⁶ Department of Gastroenterology, Carilion Clinic, Roanoke, Virginia, United States
⁷ Endoscopy Center, Shengjing Hospital of China Medical University, Shenyang, China
⁸ Division of Gastroenterology and Hepatology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States
⁹ Department of Internal Medicine, SoonChunHyang University College of Medicine, Bucheon Hospital, Bucheon/Seoul, Republic of Korea
¹⁰ Division of Gastroenterology, St Vincent’s Hospital, Melbourne, Australia
¹¹ Department of Gastroenterology and Hepatology, Singapore General Hospital, Singapore
¹² Division of Gastroenterology, Department of Medicine, King Chulalongkorn Memorial Hospital, Bangkok
¹³ Shivanand Desai Center for Digestive Disorders, Deenanath Mangeshkar Hospital and Research Center, India
¹⁴ Eastern Virginia Medical School, Norfolk, Virginia, United States

submitted 23.2.2019
accepted after revision 10.4.2019

ABSTRACT

Background and study aims The aim of the current study was to review the outcomes of a large-scale international registry on endoscopic ultrasound-guided gallbladder drainage (EGBD) that encompasses different stent systems in patients who are at high-risk for cholecystectomy.

Patients and methods This was a retrospective international multicenter registry on EGBD created by 13 institutions around the world. Consecutive patients who received EGBD for several indications were included. Outcomes include technical and clinical success, unplanned procedural events (UPE), adverse events (AEs), mortality, recurrent cholecystitis and learning curve of the procedure.

Results Between June 2011 and November 2017, 379 patients were recruited to the study. Technical and clinical success were achieved in 95.3% and 90.8% of the patients, respectively. The 30-day AE rate was 15.3% and 30-day mortality was 9.2%. UPEs were significantly more common in patients with EGBD performed for conversion of cholecystostomy and symptomatic gallstones (P<0.001); and by endoscopists with experience of fewer than 25 procedures (P=0.033). Both presence of clinical failure (P=0.014; RR 8.69 95%CI [1.56–48.47]) and endoscopist experience with fewer than 25 procedures (P=0.002; RR 4.68 95%CI [1.79–12.26]) were significant predictors of 30-day AEs.

* Meeting presentations: Digestive Disease Week 2018

Bibliography
DOI https://doi.org/10.1055/a-0915-2098 | Endoscopy International Open 2019; 07: E964–E973
© Georg Thieme Verlag KG Stuttgart · New York
eISSN 2196-9736

Corresponding author
Prof. Anthony Y.B. Teoh, Department of Surgery, Prince of Wales Hospital, Shatin, New Territories, Hong Kong SAR
Fax: +852-35057974
anthonyteoh@surgery.cuhk.edu.hk
Presence of 30-day AEs was a significant predictor of mortality \( (P<0.001; \text{RR} 103 95\%CI [11.24–944.04]). \)

**Conclusion** EGBD was associated with high success rates in this large-scale study. EGBD performed for indications other than acute cholecystitis was associated with higher UPEs. The number of cases required to gain competency with the technique by experienced interventional endosonographers was 25 procedures.

**Introduction**

Endoscopic ultrasound-guided gallbladder drainage (EGBD) was first described in 2007 [1]. Initially, the procedure was performed with plastic stents but they are prone to leakage or migration. Use of lumen-apposing stents (LAMS) and EUS-specific stents can potentially overcome these problems and the availability of these devices has dramatically changed the scope of endoscopic ultrasound-guided drainage procedures [2]. For gallbladder drainage, a number of studies have reported outcomes in small cohorts of patients and a meta-analysis reported pooled outcomes in 166 patients \([3–8]\). Outcomes from a large study cohort employing different stent systems, however, are lacking. Thus, the aim of the current study was to report the results of an international registry on EGBD employing different stent systems in patients who are at high risk for cholecystectomy. Furthermore, the learning curve and predictors to adverse events (AEs) and mortality of the procedure were addressed.

**Patients and methods**

This was a retrospective, international, multicenter registry on EGBD created by 13 institutions around the world. The institutional ethics committees of the respective hospitals approved the study protocol. Consecutive patients who received EGBD planned and attempted for symptomatic gallstones, acute cholecystitis or conversion of percutaneous cholecystostomy (PC) were included. The diagnosis of acute cholecystitis was made according to the revised Tokyo guidelines \([9,10]\). All patients were considered unfit for cholecystectomy if they satisfied one or more of the following criteria: Age \(\geq 80\) years, American society of anesthesiology (ASA) grade 3 or above, age-adjusted Charlson score \(\geq 4\) and/or Karnofsky score < 50 \([11–14]\). The anesthesiologist and surgeons at the respective hospitals jointly made the decisions. Conversion of percutaneous cholecystostomy to EGBD was performed when the patient required long-term placement of cholecystostomy tubes \([15]\). Patients with the following conditions were excluded: suspected gangrene or perforation of the gallbladder, liver abscess or pancreatitis, altered anatomy of the upper gastrointestinal tract, pregnancy, decompenated liver cirrhosis, portal hypertension and/or gastric varices, abnormal coagulation: international normalized ratio > 1.5 and/or platelets < 50,000/mm\(^3\). Of the patients included in the current study, 88 were used in other submissions \([7,16–18]\).

**Types of stents used for EGBD**

EGBD was performed with a variety of LAMS and stents with antimiigration designs \([2,19,20]\). The stents were further divided into single-step or multiple-step devices \([5–8,19,21–25]\). The single-step device allows for single-step delivery of the stent without the need to change instruments for track dilation. This included the HOT AXIOS stent \((15\times10\) mm or \(10\times10\) mm diameter, Boston Scientific, Marlborough, Massachusetts, United States) \(\text{Fig. 1a}\). Multistep devices require track dilation with a cystotome and a 4- to 6-mm biliary balloon. Types of stents used included the SPAXUS stent \((10\times10\) mm and \(10\times16\) mm, Niti-S, Taewoong Medical, Korea) \(\text{Fig. 1b}\), the BONA-AL stent \((10\) mm \(\times\) 4 to 7 cm in length with 22-mm external flares to prevent migration, Standard Sci Tech Inc., Seoul, Korea) \(\text{Fig. 1c}\) and the Microtech stent \((10\times35\) mm length, Nan Jing Co. Ltd., China) \(\text{Fig. 1d}\). All procedures were performed by experienced interventional endosonographers.

**EUS-guided gallbladder drainage procedure**

The procedures were performed under conscious sedation or monitored anesthesia by dedicated endosonographers who were competent in performing advanced interventional EUS (including drainage of pancreatic fluid collections and bile ducts) in the respective hospitals. The gallbladder was identified by a linear echoendoscope and a suitable puncture site in the stomach or the duodenum without intervening blood vessels was located. One of the two methods were used for placement of stents \(\text{Fig. 1}\). In the conventional method, the gallbladder was first punctured with a 19-gauge needle and the position was confirmed by aspiration of bile or contrast injection \([7,19,21–23]\). A 0.025” or 0.035” guide wire was passed through the needle and looped in the gallbladder. For centers using the single-step devices, the delivery system was inserted directly into the gallbladder with cautery. In those that use other stents, the needle track was dilated by a cystotome and a 4- to 6-mm biliary balloon. The delivery system of the stent was then inserted. For the direct puncture method, the gallbladder was directly punctured with the delivery system of the HOT AXIOS stent \((\text{Boston Scientific, Marlborough, Massachusetts, United States})\) \([5,6,24,25]\). For both methods, after the delivery system of stents were inserted into the gallbladder, the distal flange of the stent was deployed under EUS guidance and the proximal flange deployed within the endoscope channel or under endoscopic guidance. Once deployed, the gallbladder was completely emptied by suction and irrigation until the effluent through the stent was clean.
Post-procedural management

Patients were monitored after the procedure and fluid diets were resumed the next day if they were afebrile and had presence of flatus or bowel output. Diets were then stepped-up to regular diet if they tolerated fluid.

Follow-up management

The stents were either placed permanently for long-term drainage or a scheduled peroral cholecystoscopy was performed at 1 to 3 months for gallstone retrieval [20, 26]. In centers where a follow-up peroral cholecystoscopy was performed, it was done under carbon dioxide insufflation with a 9.8-mm magnifying endoscope equipped with water-jet irrigation (GIF-H290Z, Olympus, Tokyo, Japan). Gallstones were retrieved with standard ERCP devices and the stents were removed when the gallbladder were stone free.

Outcome parameters

Outcomes reviewed included technical and clinical success, unplanned procedural events (UPEs), 30-day AEs, 30-day mortality, recurrence rates and learning curve of the procedure. Technical success was defined as successful placement of a stent with immediate drainage of bile. Clinical success was defined as successful placement of a stent with improvement in clinical symptoms after placement of stents. Post-procedural management

Statistical analyses

Statistical analyses were performed using SPSS 20.0 statistical software (SPSS, Chicago, Illinois, United States). Comparisons were made by Chi-squared or Fisher exact test for categorical data, Wilcoxon signed-rank test for non-parametric continuous data. Predictors of UPEs, AEs and mortality were analyzed by logistic regression analysis using the enter method. A two-sided P value < 0.05 was considered significant.

Results

Between June 2011 and November 2017, 379 patients were recruited to the study. Background demographics are shown in Table 1. Indications for EUS-guided gallbladder drainage were acute cholecystitis (86.3 %), conversion of cholecystostomy (9 %) and symptomatic gallstones (4.7 %). The majority of patients had EGBD performed with the AXIOS stent (75.2 %), followed by BONA-AL (12.1 %), Microtech (7.7 %) and SPAXUS (2.4 %) stents. Technical and clinical success were achieved in 95.3 % and 90.8 % of patients, respectively. Mean (S.D.) procedural time was 60 minutes (58.4). UPEs occurred in 9.2 % of patients. The mean (S.D.) hospital stay was 9.0 days (8.3) and follow-up duration was 433.6 days (505.1). The 30-day AE rate was 15.3 % and the 30-day mortality rates was 9.2 %. Types of 30-day AEs are shown in Supplementary Table 1. Nine patients in the cohort (2.4 %) suffered from recurrent cholecystitis.

The study cohort was then divided into several subgroups for analysis. We first compared outcomes of patients with and without UPEs (Table 2). In patients with UPEs, significantly more had EGBD performed for conversion of cholecystostomy and symptomatic gallstones (P<0.001). Furthermore, endoscopists with experience with fewer than 25 procedures had significantly more UPEs (P=0.033). Presence of UPEs also resulted in significantly longer hospital stay (P=0.002) while no difference in 30-day AEs and mortality was observed.

Outcomes of procedures performed by endoscopists with experience of <25 versus ≥25 EGBD procedures were then compared (Table 3). Endoscopists who had done fewer than 25 of the procedures had significantly more procedures that were longer than 30 minutes (P=0.006), more UPEs (P=0.012) and more 30-day AEs (P=0.031). When comparing outcomes of different stent systems (Supplementary Table 2), significant differences were present in occurrence of UPEs (P=0.028), percentage of procedures performed by endoscopist with fewer than 25 procedures (P<0.001) and the 30-day AEs.

Multivariate analyses to assess for predictors of 30-day AEs (Table 4) and mortality (Table 5) were then performed. Both presence of clinical failure (P<0.014; RR 8.69 95 %CI [1.56–48.47]) and procedure performed by endoscopists with experience with fewer than 25 procedures (P=0.002; RR 4.68 95 %CI [1.79–12.26]) were significant predictors of 30-day AEs. While only presence of 30-day AEs was a significant predictor of mortality (P<0.001; RR 103 95 %CI [11.24–944.04]).
Table 1  Background demographics and outcomes.

|                      | EGBD  
|----------------------|---------
|                      | N = 379 |
| Age (years)          | 73.6 (15.0) |
| Sex (M/F)            | 199/180 (52.5 %/47.5 %) |
| Mean (S.D.) age-adjusted Charlson comorbidity index | 5.9 (3.1) |

**Indication**

- Acute cholecystitis
- Conversion of cholecystostomy
- Symptomatic gallstones

**Types of stents used**

- AXIOS 285 (75.2 %)
- Bona–AL 56 (14.8 %)
- Microtech 29 (7.7 %)
- SPAXUS 9 (2.4 %)

EGBD, endoscopic ultrasound-guided gallbladder drainage

Table 2  Comparison of patient outcomes in those with or without unplanned procedural events.

|                      | With UPE  
|----------------------|---------
|                      | N = 35  |
|                      | Without UPE  
|                      | N = 344  |
|                      | P value  |
| Age-adjusted Charlson comorbidity index > 6 (%) | 11 (32.4) | 101 (29.4) | 1 |
| Indication for EGBD (%) |                      |
| Acute cholecystitis | 22 (62.9) | 305 (88.7) | <0.001  |
| Conversion of cholecystostomy | 8 (22.9) | 26 (7.6) |  |
| Symptomatic gallstones | 5 (14.3) | 13 (3.8) |  |
| Severity of acute cholecystitis (TG grading) (%) |                      |
| 1 | 3 (20) | 81 (39.5) | 0.324 |
| 2 | 10 (66.7) | 103 (50.2) |  |
| 3 | 2 (13.3) | 21 (10.2) |  |
| Stent type (%) |                      |
| AXIOS | 24 (68.6) | 261 (75.9) | 0.028  |
| SPAXUS | 0 (0) | 9 (2.6) |  |
| Bona–AL | 4 (11.4) | 52 (15.1) |  |
| Microtech | 7 (20) | 22 (6.4) |  |
| Endoscopist experience (%) |                      |
| <25 | 23 (65.7) | 148 (43) | 0.033  |
| 25–50 | 10 (28.6) | 150 (43.6) |  |
| >50 | 2 (5.7) | 46 (13.4) |  |
| 30-day adverse events (%) |                      |
| 8 (22.9) | 50 (14.5) | 0.216 |
| 30-day mortality (%) | 4 (11.4) | 31 (9) | 0.549 |
| Hospital stay (SD) (days) | 13.5 (9.1) | 8.5 (8.0) | 0.002  |

UPE, unplanned events; EGBD, endoscopic ultrasound-guided gallbladder drainage; SD, standard deviation.

1 Indicates significance.
Discussion

The current study is the first large-scale study reporting outcomes of EGBD using different stent systems for gallbladder drainage in patients at high risk for cholecystectomy. Overall, the procedure is associated with high technical and clinical success rates with acceptable AE rates. On subgroup analysis, UPEs were significantly higher in EGBD performed for indications other than acute cholecystitis, by endoscopist with experience with fewer than 25 procedures and resulted in longer hospital stay. Furthermore, significantly more procedures performed by endoscopists with experience with fewer than 25 procedures had longer duration, UPEs, and 30-day AEs. On multivariate analysis, presence of clinical failure and endoscopist experience with fewer than 25 procedures were significant predictors of AEs while only presence of 30-day AEs was a significant predictor of mortality.

Findings from the current study are interesting in several ways. First, rates of UPE were higher in EGBD performed for indications other than acute cholecystitis, by endoscopist with experience with fewer than 25 procedures and resulted in longer hospital stay. Furthermore, significantly more procedures performed by endoscopists with experience with fewer than 25 procedures had longer duration, UPEs, and 30-day AEs. On multivariate analysis, presence of clinical failure and endoscopist experience with fewer than 25 procedures were significant predictors of AEs while only presence of 30-day AEs was a significant predictor of mortality.

Unplanned procedural events (%)

| Procedure | ≤ 30 minutes | > 30 minutes |
|-----------|--------------|--------------|
| Yes       | 161 (94.2)   | 185 (88.9)   |
| No        | 10 (5.8)     | 23 (11.1)    |

Clinical success (%)

| Procedure | Yes | No |
|-----------|-----|----|
| ≤ 30 minutes | 153 (89.5) | 18 (10.5) |
| > 30 minutes   | 197 (94.7)   | 11 (5.3)   |

Unplanned procedural events (%)

| Procedure | Yes | No |
|-----------|-----|----|
| ≤ 30 minutes | 23 (13.5) | 12 (5.8) |
| > 30 minutes    | 148 (86.5) | 196 (94.2) |

30-day adverse events (%)

| Procedure | Yes | No |
|-----------|-----|----|
| ≤ 30 minutes | 34 (19.2) | 24 (11.5) |
| > 30 minutes    | 137 (80.1) | 184 (88.5) |

30-day mortality (%)

| Procedure | Yes | No |
|-----------|-----|----|
| ≤ 30 minutes | 18 (10.5) | 17 (8.2) |
| > 30 minutes    | 153 (89.5) | 191 (91.8) |

EGBD, endoscopic ultrasound-guided gallbladder drainage

Indicates significance.
contrast to pancreatic fluid collections, the gallbladder is a freely mobile organ and the margin of error for EGBD is considerably larger. Thus, those attempting EGBD should only do so when they are familiar with other types of EUS drainage procedures that incur similar basic procedural steps including needle puncture, track dilation, and stent insertion. Furthermore, endosonographers performing EGBD in this study were already skilled at performing other types of interventional EUS procedures. Thus, their learning curves would be different than those of endoscopists just starting to perform interventional EUS. The number of procedures required to gain competency in this manuscript will need to be validated in future prospective studies.

EGBD is gaining popularity as an alternative to gallbladder drainage in patients at high risk for cholecystectomy worldwide (▶Table 6). In a pooled analysis including 166 cases, the overall technical success rate, clinical success rate, and frequency of AEs were 95.8%, 93.4%, and 12.0%, respectively [8]. A number of retrospective comparative studies have shown that compared to percutaneous cholecystostomy, EGBD is associated with fewer AEs, shorter hospital stays, and fewer reinterventions and unplanned readmissions [3–7]. This is mainly due to cholecystostomy tube-related AEs, including dislodgement, migration, obstruction, and peritubal leakage. Furthermore, long-term outcomes of EGBD appear to be favorable, with a late AE rate of 7.1% and a rate of recurrent cholecystitis of 3.2% in one study [17]. Tose rates are comparable to the 2.4% rate of recurrent cholecystitis reported in this study.

There are a number of limitations to the current study. First, the retrospective nature makes the data prone to selection and lead time bias. Second, the comparison of outcomes of different stent systems needs to be interpreted with caution. These outcomes could be influenced by the endoscopist’s experience and other factors, and may not be solely attributable to the properties of the stent systems. Finally, this study did not address how EGBD compared to other drainage procedures and no conclusion could be drawn about superiority or inferiority. An ongoing randomized controlled trial (NCT02212717) comparing EGBD versus percutaneous cholecystostomy is expected to provide more evidence to the procedures.
| Author Year | Groups | Stent | No. of patients | Technical success (%) | Clinical success (%) | Adverse events (%) | Length of stay (days) | Reintervention (%) | Recurrent cholecystitis | Mortality |
|-------------|--------|-------|-----------------|-----------------------|---------------------|-------------------|---------------------|-------------------|----------------------|---------|
| Choi 2014 [17] | EUS-GBD | BONA-AL | 63 | 62 (98.4) | 62 (98.4) | 3 (4.8) | NA | 2 (3.6) | 2 | 0 |
| Walter 2016 [22] | EUS-GBD | AXIOS | 30 | 27 (90) | 26 (86.7) | 4 (13) | NA | NA | 2 | 5 |
| Kahaleh 2016 [31] | EUS-GBD | Plastic FCSEM AXIOS | 35 | 32 (91.4) | 31 (89) | 8 (22) | NA | NA | 2 | NA |
| Dollhopf 2017 [24] | EUS-GBD | AXIOS | 75 | 74 (98.7) | 72 (95.9) | 8 (10.7) | NA | NA | 3 | 7 |
| Jang 2012 [3] | EUS-GBD | Nasogallbladder | 30 | 29 (96.7) | 29 (96.7) | 2 (6.7) | NA | NA | NA | NA |
| | PT-GBD | | 29 | 28 (96.6) | 27 (93.1) | 1 (3.4) | | | | |
| Kedia 2015 [4] | EUS-GBD | Biliary | 30 | 30 (100) | 26 (86.7) | 4 (13.3) | 7.6 | 4 (13.3) | NA | NA |
| | PT-GBD | FCSEMS | 43 | 42 (97.6) | 42 (97.6) | 17 (39.5) | 16.3 | 23 (53.4) | | |
| Teoh 2017 [7] | EUS-GBD | AXIOS | 59 | 57 (96.6) | 53 (89.8) | 19 (32.2) | 9.5 | 1 (1.7) | 0 | 5 |
| | PT-GBD | | 59 | 59 (100) | 56 (94.9) | 44 (74.6) | 11.2 | 16 (27.1) | 4 | 1 |
| Irani 2017 [6] | EUS-GBD | AXIOS | 45 | 44 (98) | 43 (96) | 5 (11) | 4.5 | 11 | 3 | 1 |
| | PT-GDB | | 45 | 45 (100) | 41 (91) | 14 (32) | 16.1 | 112 | 4 | 3 |
| Tyber 2018 [5] | EUS-GBD | AXIOS | 42 | 40 (95) | 40 (95) | 9 (21.4) | 8.3 | 4 (240) | 3 | 0 |
| | PT-GBD | | 113 | 112 (99) | 97 (86) | 24 (21.2) | 17.5 | 28 (10) | 9 | 4 |

EUS-GBD, endoscopic ultrasound-guided gallbladder drainage; PT-GBD, percutaneous gallbladder drainage; NA, not assessed
Conclusion

In conclusion, EGBD with different stent systems is associated with high technical and clinical success rates in this large-scale study. EGBD performed for indications other than acute cholecystitis was associated with higher UPEs. Endoscopist experience is an important parameter for outcomes and the number of cases required to gain competency with the technique is approximately 25 procedures. Clinical failure and endoscopist experience were predictors of 30-day AEs and the presence of 30-day AEs was a predictor of mortality.

Competing interests

Dr. Teoh is a consultant for Boston Scientific, Cook, Taewoong, Cook and Microtech Medical Corporations. Dr. Baron is a consultant for Boston Scientific Medical Corporation. Dr. Moon is a consultant for Taewoong Medical Corporation. Dr. Siyu is a consultant for Microtech Medical Corporation. Dr. Kunda is a consultant for Boston Scientific, Omega Medical Imaging, and BCM Korea.

References

[1] Baron TH, Topazian MD. Endoscopic transduodenal drainage of the gallbladder: implications for endoluminal treatment of gallbladder disease. Gastrointestinal endoscopy 2007; 65: 735–737
[2] Teoh AY, Ng EK, Chan SM et al. Ex vivo comparison of the lumen-apposing properties of EUS-specific stents (with video). Gastrointest Endosc 2016; 84: 62–68
[3] Jang JW, Lee SS, Song TJ et al. Endoscopic ultrasound-guided transmural and percutaneous transhepatic gallbladder drainage are comparable for acute cholecystitis. Gastroenterology 2012; 142: 805–811
[4] Keda P, Sharaila RZ, Kumta NA et al. Endoscopic gallbladder drainage compared with percutaneous drainage. Gastrointest Endosc 2015; 82: 1031–1036
[5] Tyberg A, Saumoy M, Sequeiros EV et al. EUS-guided Versus Percutaneous Gallbladder Drainage: Isn’t It Time To Convert? J Clin Gastroenterol 2018; 52: 79–84
[6] Irani S, Ngamruengphong S, Teoh A et al. Similar efficacies of endoscopic ultrasound gallbladder drainage with a lumen-apposing metal stent versus percutaneous transhepatic gallbladder drainage for acute cholecystitis. Clin Gastroenterol Hepatol 2017; 15: 738–745
[7] Teoh AYB, Serna C, Penas I et al. Endoscopic ultrasound-guided gallbladder drainage reduces adverse events compared with percutaneous cholecystostomy in patients who are unfit for cholecystectomy. Endoscopy 2017; 49: 130–138
[8] Anderloni A, Buda A, Vieceli F et al. Endoscopic ultrasound-guided transmural stenting for gallbladder drainage in high-risk patients with acute cholecystitis: a systematic review and pooled analysis. Surg Endosc 2016; 30: 5200–5208
[9] Yokoe M, Hata J, Takada T et al. Tokyo Guidelines 2018: diagnostic criteria and severity grading of acute cholecystitis (with videos). J Hepato-biliary-pancreatic Sci 2018; 25: 41–54
[10] Mori Y, Itoi T, Baron TH et al. Tokyo Guidelines 2018: management strategies for gallbladder drainage in patients with acute cholecystitis (with videos). J Hepato-biliary-pancreatic Sci 2018; 25: 87–95
[11] Turrentine FE, Wang H, Simpson VB et al. Surgical risk factors, morbidity, and mortality in elderly patients. J Am Coll Surg 2006; 203: 865–877
[12] Yi NJ, Han HS, Min SK. The safety of a laparoscopic cholecystectomy in acute cholecystitis in high-risk patients older than sixty with stratification based on ASA score. Minim Invasive Ther Allied Technol 2006; 15: 159–164
[13] Charlson M, Szatrowski TP, Peterson J et al. Validation of a combined comorbidity index. J Clin Epidemiol 1994; 47: 1245–1251
[14] Yates JW, Chalmer B, McKegeen FP. Evaluation of patients with advanced cancer using the Karnofsky performance status. Cancer 1980; 45: 2220–2224
[15] Law R, Grimm IS, Stavas JM et al. Conversion of percutaneous cholecystostomy to internal transmural gallbladder drainage using an endoscopic ultrasound-guided, lumen-apposing metal stent. Clin Gastroenterol Hepatol 2016; 14: 476–480
[16] de la Serna-Higuera C, Perez-Miranda M, Gil-Simon P et al. EUS-guided transenteric gallbladder drainage with a new fistula-forming, lumen-apposing metal stent. Gastrointest Endosc 2013; 77: 303–308
[17] Choi JH, Lee SS, Choi JH et al. Long-term outcomes after endoscopic ultrasonography-guided gallbladder drainage for acute cholecystitis. Endosc 2014; 46: 656–661
[18] Ge N, Sun S, Sun S et al. Endoscopic ultrasound-assisted transmural cholecystoduodenostomy or cholecystogastrostomy as a bridge for per-oral cholecystoscopy therapy using double-flanged fully covered metal stent. BMC Gastroenterol 2016; 16: 9
[19] Jang JW, Lee SS, Park DH et al. Feasibility and safety of EUS-guided transgastric/transduodenal gallbladder drainage with single-step placement of a modified covered self-expandable metal stent in patients unsuitable for cholecystectomy. Gastrointest Endosc 2011; 74: 176–181
[20] Ge N, Sun S, Sun S et al. Endoscopic ultrasound-assisted transmural cholecystoduodenostomy or cholecystogastrostomy as a bridge for per-oral cholecystoscopy therapy using double-flanged fully covered metal stent. BMC Gastroenterol 2016; 16: 9
[21] Itoi T, Binmoeller KD, Shah J et al. Clinical evaluation of a novel lumen-apposing metal stent for endosonography-guided pancreatic pseudocyst and gallbladder drainage (with videos). Gastrointest Endosc 2012; 75: 870–876
[22] Walter D, Teoh AY, Itoi T et al. EUS-guided gall bladder drainage with a lumen-apposing metal stent: a prospective long-term evaluation. Gut 2016; 65: 6–8
[23] Lee SS, Park DH, Hwang CY et al. EUS-guided transmural cholecystostomy as rescue management for acute cholecystitis in elderly or high-risk patients: a prospective feasibility study. Gastrointest Endosc 2007; 66: 1008–1012
[24] Dollhopf M, Larghi A, Will U et al. EUS-guided gallbladder drainage in patients with acute cholecystitis and high surgical risk using an electrocautery-enhanced lumen-apposing metal stent device. Gastrointest Endosc 2017; 86: 636–643
[25] Irani S, Baron TH, Grimm IS et al. EUS-guided gallbladder drainage with a lumen-apposing metal stent (with video). Gastrointest Endosc 2015; 82: 1101–1115
[26] Chan SM, Teoh AYB, Yip HC et al. Feasibility of per-oral cholecystoscopy and advanced gallbladder interventions after EUS-guided gallbladder stenting (with video). Gastrointest Endosc 2017; 85: 1225–1232
[27] Cotton PB, Eisen GM, Aabakken L et al. A lexicon for endoscopic adverse events: report of an ASGE workshop. Gastrointest Endosc 2010; 71: 446–454
[28] Harewood GC, Wright CA, Baron TH. Impact on patient outcomes of experience in the performance of endoscopic pancreatic fluid collection drainage. Gastrointest Endosc 2003; 58: 230–235

Teoh AY et al. Outcomes of an… Endoscopy International Open 2019; 07: E964–E973
[29] Varadarajulu S, Tamhane A, Blakely J. Graded dilation technique for EUS-guided drainage of peripancreatic fluid collections: an assessment of outcomes and complications and technical proficiency (with video). Gastrointest Endosc 2008; 68: 656 – 666

[30] Teoh AY, Dhir V, Kida M et al. Consensus guidelines on the optimal management in interventional EUS procedures: results from the Asian EUS group RAND/UCLA expert panel. Gut 2018; 67: 1209 – 1228

[31] Kahaleh M, Perez-Miranda M, Artifon EL et al. International collaborative study on EUS-guided gallbladder drainage: Are we ready for prime time? Dig Liver Dis 2016; 48: 1054 – 1057
### Supplementary Table 1
Types of 30-day adverse events after EGBD.

| Types of adverse events                                      | Number of patients N = 58 |
|--------------------------------------------------------------|----------------------------|
| Procedure-related                                            | Total = 20                 |
| Stent obstruction                                            | 3                          |
| Stent migration                                              | 3                          |
| Bile leak                                                    | 3                          |
| Duodenal perforation                                         | 2                          |
| Pneumoperitoneum                                             | 2                          |
| Gastric outlet obstruction from stent                        | 1                          |
| Bleeding from puncture site                                  | 1                          |
| Infected abdominal collection                                | 1                          |
| Bleeding in gallbladder                                      | 1                          |
| Bleeding from cystic artery                                  | 1                          |
| Infected ascites                                             | 1                          |
| Procedure-unrelated                                          | Total = 39                 |
| Sepsis with organ failure                                    | 12                         |
| Peptic ulcers with bleeding (away from the puncture site)    | 5                          |
| Pneumonia                                                    | 3                          |
| Congestive heart failure                                     | 3                          |
| Decompensated liver cirrhosis                               | 2                          |
| Acute coronary syndrome                                      | 2                          |
| Atrial fibrillation                                          | 1                          |
| Acute renal failure                                          | 1                          |
| Miscellaneous                                                | 10                         |

Please note that some patients had more than one 30-day adverse event.

### Supplementary Table 2
Comparison of outcomes between different stent systems.

|                                | AXIOS N = 285 | Spaxus N = 9 | Bona – AL N = 56 | Microtech N = 29 | P value |
|--------------------------------|----------------|--------------|------------------|------------------|---------|
| Technical success (%)          | 95.8 %         | 100 %        | 96.4 %           | 86.2 %           | 0.109   |
| Clinical success (%)           | 89.8 %         | 100 %        | 94.6 %           | 89.7 %           | 0.520   |
| Unplanned procedural events (%)| 8.4 %          | 0 %          | 7.1 %            | 24.1 %           | 0.028†  |
| Endoscopist experience < 25 (%)| 46 %           | 100 %        | 10.7 %           | 86.2 %           | <0.001† |
| 30-day adverse events (%)      | 18.2 %         | 11.1 %       | 7.1 %            | 3.4 %            | 0.045†  |
| 30-day mortality (%)           | 11.1 %         | 11.1 %       | 1.8 %            | 3.4 %            | 0.100   |

† Indicates significance. Chi-squared test used for categorical data. Wilcoxon signed-rank test for non-parametric continuous data.